SHM Converge Scientific Abstract ePoster Gallery-Remdesivir Reduces All-Cause and Covid-19 Related Readmission After Initial Hospitalization

Pdf Summary

This retrospective cohort study evaluated whether remdesivir (RDV) use during an initial COVID-19 hospitalization was associated with lower 30-day readmission risk. Using the PINC AI Healthcare Database, investigators analyzed 590,493 adults discharged alive from 1,009 U.S. hospitals between May 2020 and April 2023. About 55% received RDV.<br /><br />Patients who were readmitted were older and had more comorbidities than those not readmitted. Compared with non-RDV patients, RDV-treated patients were somewhat younger, had higher illness severity, and were more likely to require supplemental oxygen or ICU care during the index hospitalization.<br /><br />Key findings:<br />- All-cause 30-day readmission occurred in 7.7% of RDV patients vs 10.1% of non-RDV patients.<br />- COVID-19-related 30-day readmission occurred in 3.6% of RDV patients vs 5.8% of non-RDV patients.<br /><br />After adjustment for age, corticosteroid use, comorbidity burden, oxygen requirement, variant period, and ICU stay, RDV remained associated with significantly lower odds of readmission:<br />- All-cause readmission: aOR 0.76 (95% CI 0.75–0.78)<br />- COVID-19-related readmission: aOR 0.63 (95% CI 0.61–0.65)<br /><br />The benefit was consistent across patients with no supplemental oxygen and those requiring any supplemental oxygen level, including low-flow oxygen, high-flow oxygen/non-invasive ventilation, and invasive mechanical ventilation/ECMO.<br /><br />Among readmission diagnoses, the most common was COVID-19 itself (29.1%), followed by sepsis and pneumonia.<br /><br />Overall, the study suggests that remdesivir use during the initial COVID-19 hospitalization was associated with a significantly reduced likelihood of both all-cause and COVID-19-related 30-day readmission across pandemic variant periods through April 2023.

Asset Subtitle

Essy Mozaffari

Meta Tag

Author List Aastha Chandak, Alpesh N. Amin, Andre C. Kalil, Chidinma Chima-Melton, Essy Mozaffari, Mark Berry, Robert L. Gottlieb, Thomas Oppelt, Vishnudas Sarda

Category Research

Concept Remdesivir

Concept 30-Day Readmission

Concept Retrospective Cohort Study

Concept All-Cause Readmission

Concept COVID-19-related readmission

Distinguished Non-Finalist

Presenter Organization Gilead Sciences, Foster City, California

Presenting Author Essy Mozaffari

Track Outcomes Research

Keywords

remdesivir

COVID-19 hospitalization

30-day readmission

retrospective cohort study

PINC AI Healthcare Database

all-cause readmission

COVID-19-related readmission

adjusted odds ratio

supplemental oxygen

ICU care

Remdesivir

30-Day Readmission

Retrospective Cohort Study

All-Cause Readmission

COVID-19-related readmission